During a retroactive review of past complaints for potential adverse events, conducted as a capa in response to a recent fda inspection, a reportable adverse event was discovered.A nurse contacted zoll customer support on (b)(6) 2011 to report that a (b)(6) male patient was treated.The nurse stated that the patient reported walking into (b)(6) when he started to feel light-headed and lost consciousness.The patient reported that he did not remember being shocked.The nurse reported that the patient fell and has a broken hip.The patient underwent surgery on (b)(6) 2011.
|
Per review of the treatment event, the patient experienced an inappropriate defibrillation event on (b)(6) 2011 at 12:34pm.Signal artifact contributed to the false detection.The response buttons were not used during the event.There are no allegations that the inappropriate defibrillation caused or contributed to the patient's fail; however, zoll cannot definitively rule out the inappropriate treatment as a contributing cause of the fall and resulting serious injury.Device evaluation summary: device evaluation of monitor sn: (b)(4) and electrode belt sn: (b)(4) were completed.The monitor and electrode belt were fully functional upon receipt.Monitor sn: (b)(4), electrode belt sn (b)(4): 11/2013 - reuse.Additional inappropriate defibrillation narrative: inappropriate defibrillations are an anticipated risk associated with the use of the lifevest.Patients are instructed through alarms, voice messages, ifu, and training to press the response buttons to prevent an inappropriate defibrillation.The current commercial inappropriate defibrillation rate is consistent with the observed rate during the pivotal clinical trial (b)(4).A summary of the safety and effectiveness data (ssed), including the inappropriate defibrillation safety objective supporting fda's approval of the lifevest, can be found at http://www.Accessdata.Fda.Gov/cdrh_docs/pdf/p010030b.Pdf.
|